Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751504 | 0.90 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1PLA2G2AKDM4ELMNA | |
| SCHEMBL1064220 | 0.90 | L3MBTL1 (0.64) | L3MBTL1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL4698950 | 0.86 | KDM4E (0.58) | L3MBTL1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL4789201 | 0.83 | HRH1 (0.42) | ALDH1A1PLA2G2A | |
| SCHEMBL14177944 | 0.82 | PLA2G2A (0.40) | ALDH1A1PLA2G2AKDM4EMEN1KMT2A | |
| SCHEMBL5118981 | 0.81 | ALDH1A1 (0.40) | ALDH1A1PLA2G2AKDM4ELMNAMAPT | |
| SCHEMBL1063465 | 0.81 | KDM4E (0.69) | ALDH1A1KDM4ELMNAMAPTPKM | |
| SCHEMBL7157620 | 0.79 | KDM4E (0.67) | ALDH1A1KDM4ELMNAMAPTPKM | |
| SCHEMBL12932651 | 0.77 | L3MBTL1 (0.69) | L3MBTL1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL4699355 | 0.76 | RECQL (0.63) | L3MBTL1ALDH1A1GAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466681-A | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2009-06-24 | — | — | CN | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | L3MBTL1 3091/4885ALDH1A1 2365/4885PLA2G2A 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.